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In a German cohort of 661 melanoma patients the performance, costs and survival beneﬁts of staging methods (history and
physical examination; chest X-ray; ultrasonography of the abdomen; high resolution sonography of the peripheral lymph
nodes) were assessed at initial staging and during follow-up of stage I/II+III disease. At initial staging, 74% (23 out of 31) of
synchronous metastases were ﬁrst detected by physical examination followed by sonography of the lymph nodes revealing
16% (5 out of 31). Other imaging methods were less efﬁcient (Chest X-ray: one out of 31; sonography of abdomen: two out
of 31). Nearly 24% of all 127 ﬁrst recurrences and 18% of 73 second recurrences developed in patients not participating in the
follow-up programme. In follow-up patients detection of ﬁrst or second recurrence were attributed to history and physical
examination on a routine visit in 47 and 52% recurrences, respectively, and to routine imaging procedures in 21 and 17% of
cases, respectively. Lymph node sonography was the most successful technical staging procedure indicating 13% of ﬁrst
relapses, but comprised 24% of total costs of follow-up in stage I/II. Routine imaging comprised nearly 50% of total costs for
follow-up in stage I/II and in stage III. The mode of detecting a relapse (‘patient vs. doctor-diagnosed’ or ‘symptomatic vs
asymptomatic’) did not signiﬁcantly inﬂuence patients overall survival. Taken together, imaging procedures for routine follow-
up in stage I/II and stage III melanoma patients were inefﬁcient and not cost-efﬁcient.
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At present, physician’s intuition and sense of responsibility, but not
solid data, justify the extensive and costly postoperative procedures
used to perform follow-up of cutaneous melanoma patients. There
is no consensus on the best follow-up program for patients with
resected primary melanoma, nor is there much data to help oncol-
ogists achieve such agreement (Kersey et al, 1985; Conference,
1992; Rumke et al, 1992; Orfanos et al, 1994; Romero et al,
1994; Basse `res et al, 1995; Shumate et al, 1995; Eggermont, 1996;
Ross, 1996; Provost et al, 1997; Huang et al, 1998; Mooney et al,
1998; Poo-Hwu et al, 1999; Hormbrey et al, 2000).
German follow-up guidelines for melanoma call for regular
history and physical examination, blood tests and chest X-ray, also
for ultrasonography of the abdomen and high resolution ultrasono-
graphy of the peripheral lymph nodes (Orfanos et al, 1994).
However, only few studies deal with the efﬁcacy of sonographic
abdominal screening (Basse `res et al, 1995; Bastien et al, 1997),
and there are no large scale reports published on the usefulness
of ultrasonography of the peripheral lymph nodes for screening
purposes. In addition, studies hardly ever analyse the costs of
follow-up methods in relation to their screening success, and only
few try to show any inﬂuence of the mode of recurrence detection
on patient survival (Baughan et al, 1993; Basse `res et al, 1995;
Shumate et al, 1995; Poo-Hwu et al, 1999). Based on these facts,
there is an urgent need to establish standardised protocols for
follow-up that balance costs and use of medical resources with
patients’ beneﬁts. In the absence of prospective data, this study
attempts to pave the way by performing a systematic retrospective
evaluation of the records of 661 patients with melanoma stages I–
III who had been seen and, for the most part, followed between
January 1983 and November 1999 at the Department of Dermatol-
ogy at the University Hospital Mannheim.
PATIENTS AND METHODS
Patient selection
Out of 870 medical records from melanoma patients that could be
traced in the archives, 661 records (630 stage I/II, 27 stage IIIA/B,
four stage IV patients at time of ﬁrst diagnosis) from January 1983
to November 1999 were selected as a historical cohort for further
evaluation. The year 1983 was chosen as a starting point because
existing follow-up guidelines have only been slightly modiﬁed since
then (addition of lymph node sonography to routine follow-up in
1986; extension of the follow-up period from 8–10 years in 1994).
These 661 records met the principal selection criteria which were
(a) management of the primary cutaneous melanoma (or of
loco-regional recurrence) and (b) proper primary documentation
at our clinic. Records were considered for evaluation of initial
staging techniques if they contained at least one documented
staging result at time of primary excision. For evaluation of
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were included. Patients’ characteristics which are of known prog-
nostic relevance for localised stage I/II disease (histological types,
site of primary melanoma, age and sex) closely resembled those
of other historical cohorts from years 1981–1990 (Baughan et al,
1993) or 1971–1995 (Mooney et al, 1998) (data not shown).
Initial staging and follow-up
Within 2 weeks of initial physical examination and deﬁnite surgical
treatment of a primary cutaneous melanoma, patients usually
underwent radiodiagnostic imaging procedures including chest X-
ray, sonography of the abdomen and high resolution sonography
of peripheral lymph nodes. In addition, patients with pT
40.75 mm frequently had scintigraphies of the bones and CT-scans
of the brain. Since 1983 the frequency and type of melanoma
follow-up procedures at our institution have been adapted to the
clinical stage, using the German DDG staging system (Orfanos,
1994) which is close to the UICC 1987 classiﬁcation system.
Routine follow-up for stage I/II patients consisted of physician visits
every 3 months during the ﬁrst 5 years, and every 6 months there-
after until the end of year 8 or recurrence detection. Chest X-ray
and sonography of the abdomen were annually done on each
patient. Lymph node sonography of peripheral nodes was routinely
performed every 6 months during the years 1986–1997 at follow-
up of patients in stage I/II. The postsurgical follow-up of patients
with loco-regional recurrence were usually extended by increasing
the frequency of diagnostic imaging (Chest X-ray+sonography of
abdomen twice a year, sonography of lymph nodes four times a
year). Until 1997 blood tests (complete blood count, liver trans-
aminases, LDH) were done at every patients’ visit during follow-up.
Data acquisition and analyses
The following information was extracted and entered into a Micro-
soft ACCESS
197 (SR-21) data base: patients’ primary data,
survival status, diagnosis of synchronous or metachronous secondary
malignant melanoma or other cutaneous malignancies, time points
of each physical examination/diagnostic imaging procedure at initial
staging and during follow-up of stage I/II or stage patients and their
results (negative [neg]; false-positive [fp]; true-positive [tp], time
point and detection method of ﬁrst and/or second relapse). Results
and number of all subsequent imaging procedures caused by false-
positive results of routine tests during initial staging and follow-up
at any clinical stage were carefully collected (repetition of same test,
other diagnostic methods, e.g. CT- or NMR-scans). Missing informa-
tion on mode of recurrence detection or survival status was obtained
by means of questionnaires and telephone calls to the patient or
surviving close family members. Evaluation was discontinued when
patient developed a 2nd recurrence or distant metastatic disease.
For descriptive analysis and survival analysis data were transferred
from ACCESS
1 into SPSS
1 for Windows (Release 10.0.7). This soft-
ware package also provided algorithms for the Kaplan–Meier
method of analysis for actuarial survival, with comparisons between
survival curves calculated using the log-rank test. ‘Detection rate’ of a
given diagnostic method was deﬁned as the percentage of relapses
revealed by this test only and not by any other simpler and cheaper
method. The costs of initial staging and follow-up at clinical stage
I/II and stage III were calculated on basis of the year 2000 price scale
for outpatient treatment (‘GOA ¨’) within the German Public Health
Care System, neglecting lower price levels during the last 17 years.
All subsequent imaging procedures and costs caused by false-positive
results obtained from a given diagnostic method were also documen-
ted and included in the total cost calculation.
RESULTS
Based on the entry criteria of this evaluation (see above), data were
extracted from 561/661 records. Files of 554 out of 630 stage I/II
patients and of 93 stage III patients within a median follow-up
time of 4.1 and 1.5 years, respectively, were analysed. The detection
mode of recurrent disease could be categorised in 127 stage I/II
patients presenting ﬁrst recurrences, and in all 73 stage III patients
developing second recurrences.
Recurrence pattern
In 561 out of 661 patients with primary melanoma an initial staging

























































≤ 0.75 mm 1.51–4 mm No Breslow data
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Tumour thickness categories
Figure 1 Number of documented initial staging tests performed at the
time of primary diagnosis.
Table 1 First recurrence (FR) rates in stage I/II patients by Breslow thickness
Mannheim study cohort 1983–1999
(Baughan et al, 1993) (Mooney et al, 1998)
a
Breslow thickness No. Patients No. FR Rate (%) Recurrence rates (%)
pT1 (40.75 mm) 197 8 4.1 3 2
pT2 (0.76–1.5 mm) 174 22 12.6 8 15
pT3 (1.51–4.0 mm) 152 53 34.9 32 27
pT4 (44.0 mm) 46 22 47.8 51 47
no Breslow data 61 22 36.1 ? 24
Total: 630 127
aStaging system in this study also considered Clark’s level of primary lesions.
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British Journal of Cancer (2002) 87(2), 151–157 ã 2002 Cancer Research UKnous metastases in 31 out of 561 patients. Twenty-seven out of 31
patients were upstaged to IIIA/B disease (4.7%), only four patients
(0.6%) were shown to be stage IV with asymptomatic distant metas-
tases. After excision of the primary tumour in 630 stage I/II
melanoma patients, a total of 127 (20%) FR were identiﬁed over
time. Distribution of Breslow thickness and recurrence rate among
stage I/II patients in our study group correlated well with other
study cohorts as shown in Table 1. Five hundred and ﬁfty-four
out of 630 patients participated in the follow-up programme for
more than 6 months. Ninety-ﬁve out of 127 ﬁrst relapses were
detected in the follow-up of patients in stage I/II with 88 recurrences
(90.7%) being noted in the ﬁrst 5 years and with 75 (77.3%) of the
metastases detected by the end of third year. Eight out of 197 (4.1%)
patients with a ‘low risk’ melanoma (pT 40.75 mm) relapsed; only
two after the ﬁfth year. The metastatic pattern of ﬁrst relapse is
shown in Figure 2 and was similar to other reports (Kersey et al,
1985; Fusi et al, 1993; Soong et al, 1998). Ninety-three patients with
surgically resected loco-regional metastases (24 initial stage IIIA/B
and 69 former stage I/II patients) were enrolled into the follow-up
programme, in 60 out of 93 stage III patients a relapse was docu-
mented (64.5%) within a median time of 7.8 months.
Efﬁcacy of staging methods
The detection rate including the number of false-positive results of
each staging method separated by the clinical phase (initial staging,
follow-up stage I/II and III) is given in Table 2. At initial staging,
2554 imaging procedures were performed in 561 patients yielding
31 metastases (true-positive) and 202 false-positive results leading
to further technical examinations. In follow-up of stage I/II patients
30 metastases (32%) were detected by the patient and triggering a
premature visit, however, 45 of the remaining 65 metastases
detected at this stage were detected by the doctor (Table 2). At
any phase of melanoma staging and follow-up patient’ history
and physical examination was the most successful diagnostic tool
indicating the vast majority of all relapses (around 70%) in patients
attending the follow-up program. Although lymph node sonogra-
phy was the best performing method among the imaging
procedures, detection rate was substantially lower (between 15–
20%) compared to physical examination and detection rate of
lymph node sonography notably decreased at the different phases
of melanoma disease. Chest X-ray and sonography of the abdomen
showed extremely low detection rates (below 10%) when used for
routine follow-up in stage I/II and stage III patients (Table 2). Over-
all, the detection of 65 out of 95 ﬁrst (68.5%) and 41 out of 60
second relapses (68.3%) could be attributed to the scheduled
follow-up activities. Thirty out of 127 ﬁrst relapses (24%) developed
in patients not enrolled into the follow-up programme at the time
of diagnosis. At initial staging, 325 scintigraphies of the bones and
282 cranial CT scans were performed without revealing any metas-
tases whereas lymph node sonography was remarkably effective
(16% detection rate (ﬁve out 31 metastases detected)) (Table 2).
Cost-efﬁciency of staging methods
Absolute and relative expenses (including costs caused by false-
positive results) of each staging method were summarised (Table
3). Absolute costs for clinical assessment were the highest in all
clinical phases making up to 53% of total costs for follow up.
Detection rates were high (Table 2). Costs for physical assessment
ranged between e1100 (at initial staging) to e7300 (follow-up in
stage I/II) per detected metastasis. Sonography of the lymph nodes
proved to be the most cost consuming technical screening method
with about 25% of total expenses at each phase of follow-up. Costs
ranged between e4400 at initial staging to e13300 (follow-up of
stage I/II) per detected metastasis. In contrast, total costs for
screening by chest X-ray ranged between 17.2 to 9.2% (Table 3),
however, detection rates were low (Table 2) and costs to detect a
metastasis ranged between e2800 (in stage III) to e13500 at initial
staging. Among initial staging methods, scintigraphy of bones and
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n =127 out of 630 records
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Figure 2 Distribution pattern of 127 ﬁrst recurrences in 630 FU I/II
patients. The recurrence pattern was classiﬁed into local (satellites or
in-transit metastases), regional (regional lymph nodes), distant (viscera;
distant (sub-)cutis or lymph nodes) or combinations of these locations.
Table 2 Efﬁcacy of diagnostic methods at initial staging and in follow-up of stage I/II and stage III melanoma patients
Initial staging Follow-up stage I/II Follow-up stage III
fp
b tp
b Detection fp tp Detection fp tp Detection
Method
a nn n total rate (%) nn n total rate (%) nn n total rate (%)
H&P 29 23 584 74.2 245 45 8701 47.4 40 31 1277 51.7
CXR 23 1 524 3.2 105 7 3292 7.4 11 3 419 5.0
SAB 25 2 487 6.5 101 1 2494 1.1 16 1 325 1.6
LNS 58 5 352 16.1 273 12 3050 12.6 55 6 457 10.0
SCB 62 0 325 – – – – – – – – –
CCT 5 0 282 – – – – – – – – –
Total: 202 31 2554 100 724 65 17,537 68.5 122 41 2478 68.3
Recurrences in patients followed-up, n: 95 (=100%) 60 (=100%)
aH&P: History and physical examination; CXR: chest X-ray; SAB: sonography of the abdomen; LNS: high resolution sonography of peripheral lymphnodes; SCB: szintigraphy of
the bones; CCT: cranial CT-scan.
bfp: false-positive result; tp: true-positive result.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(2), 151–157total costs. Considering ‘detection rate’ and ‘relative costs’, the efﬁ-
ciency ratio for each method clearly demonstrated the physical
examination to be superior to all other staging at all follow-up
phases. The costs for each relapse detected within each risk cate-
gory of primary tumour during follow-up in stage I/II (Table 4)
varied from e35900. (pT40.75 mm) to e2326. (pT44.0 mm).
Due to the low rate of relapses in patients enrolled into follow-
up program in stage I/II in 5th and following years, the mean price
per detected recurrence drastically increased from e5806 (+e1.289,
s.d.; years 1–4) to e18558 (+e6.706, s.d.; years 5–8).
Survival analyses
Survival after relapse was analysed by mode of detection of relapse.
There was no difference in survival between patients with sympto-
matic relapse (84%) and asymptomatic relapse (16%; Figure 3a).
Also the small subset of patients during follow-up in stage I/II in
whom a ﬁrst recurrence was detected by lymph node sonography
(n=9) did not survive signiﬁcantly longer than patients suffering
from symptomatic nodes (Figure 3b). Comparison of survival
times of patients with ﬁrst relapse classiﬁed into ‘doctor-diagnosed’
(n=48) or ‘patient-diagnosed’ (n=77, including symptomatic ‘no
follow-up’ patients) did not show signiﬁcant survival advantages
for any group (Figure 3C). Survival analyses were performed in
patients attending follow-up in stage III in the same way (‘asymp-
tomatic’ vs ‘symptomatic’; ‘doctor-’ vs ‘patient-diagnosed’) and did
not show any survival advantages (data not shown).
DISCUSSION
Initial staging
Among the radiologic diagnostic methods employed at the various
stages of melanoma disease, the examinations with chest X-ray and
sonography of the abdomen and also, frequently, the bone scans
and cranial CT scans performed for initial staging in medium/high
risk primary tumours, have received much criticism because their
diagnostic proﬁt is low and they yield a high rate of false-positive
results (Kersey et al, 1985; Ardizzoni et al, 1987; Zartman et al,
1987; Khansur et al, 1989; Terhune et al, 1998). Our data at initial
staging argue for the omission of both, chest X-ray and sonography
of abdomen at initial staging since the efﬁciency ratios of these two
methods were far below 0.5 – reﬂecting a very disadvantageous






























Survival curves after asymptomatic
or symptomatic first recurrence














0      20      40     60     80     100    120 0    10    20    30    40    50    60    70    80
Month
Survival after first relapse categorised
































Figure 3 Kaplan–Meier curves after detection of symptomatic (symp) and asymptomatic (asymp) ﬁrst recurrences in stage I/II patients (A) Comparison
of survival curves between ﬁrst relapse patients which were grouped by whether the ﬁrst recurrence was detected due to routine imaging methods in an
asymptomatic stage or clinically by patients/physicians due to symptoms (P=0.643, log-rank-test). (B) Sonography of the regional lymph node indicated a ﬁrst
relapse in 9 nine out of 95 stage I/II patients attending follow-up. Their survival was compared to n=49 patients with symptomatic regional nodes (P=0.907,
log-rank-test). (C) 125 patients were grouped according to the mode of detection of FR (‘doctor-diagnosed’ vs ‘patient-diagnosed’; P=0.565, log-rank-test).
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British Journal of Cancer (2002) 87(2), 151–157 ã 2002 Cancer Research UKCranial CT and bone scans obviously have no place in the routine
initial staging since they are quite expensive (about 67% of total
costs of the initial staging) and detected no recurrence at all in
282 and 325 patients, respectively. Only lymph node sonography
had some diagnostic value revealing lymph node metastases that
had not been detected by the physical examination previously.
Kersey et al (1985) reported similar results with two true-positive
pedal lymphangiograms in 73 patients with a lower limb melanoma
out of more than 300 patients initially staged. A detection rate of
16% (ﬁve out of 31 initial stage III/IV patients) argues for lymph
node sonography to be included in the routine work-up at initial
staging. However, with the increasing use of sentinel node biopsy
technique in primary ‘risk melanomas’ at time of primary melano-
ma excision (Reintgen et al, 1998), lymph node sonography may
turn out to be redundant.
Follow-up stage I/II
In 24% of all 127 patients with ﬁrst relapse the symptoms appeared
either in patients who had never participated in the follow-up
programme or had prematurely discontinued or had completed
the whole course of follow-up examinations. This seems to be a
surprisingly high number and has never been reported in any
previous evaluation (Basse `res et al, 1995; Bastien et al, 1997;
Mooney et al, 1998; Poo-Hwu et al, 1999). These data suggest that
thorough and reliable surveillance of melanoma patients is, in
reality, hardly possible because of the often erratic and unpredict-
able course of the disease and because of the difﬁculty of attaining
full patient compliance.
In patients attending the FU I/II program, about 68% of ﬁrst
relapses were detected due to scheduled follow-up activity. This
is a signiﬁcantly higher yield than reported by Dicker et al
(1999) who found only 26% of ﬁrst recurrences detected at the
follow-up clinic. Baughan et al (1993), Kersey et al (1985) as well
as Basse `res et al (1995) found 41, 44 and 50%, respectively, of all
ﬁrst relapses to be detected by routine follow-up activity consider-
ing only the purely doctor-diagnosed recurrences. Routine imaging
procedures contributed 21% to the overall detection rate at sched-
uled visits in this study. This detection rate is mainly due to the
routine use of lymph node sonography which was the imaging
method with the highest yield of all technical staging methods
(12 out of 95 relapses). In contrast, the yield of routine technical
examinations in stage I/II patients have previously been reported
to be much lower between 4–11%, with studies mostly reporting
the use of chest X-ray and sonography of the abdomen, but none
using sonography of the lymph nodes (Kersey et al, 1985; Goerz et
al, 1986; Basse `res et al, 1995; Weiss et al, 1995; Bastien et al, 1997;
Mooney et al, 1998).
Follow-up stage III
This is the ﬁrst study separately analysing the efﬁcacy of routine
imaging procedures in stage III patients detecting a second relapse.
Only a recent retrospective study reported on the detection mode
of SR (‘patient’ vs ‘doctor’-diagnosed) in FU III patients (Poo-
Hwu et al, 1999), however, the performance of routine imaging
procedures was not discussed. Although the frequency of imaging
procedures being employed in follow-up of stage III patients was
doubled compared to stage I/II according to the German follow-
up recommendations, this did not result in an increased detection
rate. In fact the efﬁciency ratio decreased whereas routine physical
examinations on a regular visit became the clearly dominating
mode of recurrence detection in stage III patients (31 out of 60









Table 3 Summarised cost (e) caused by each screening methods at the time of initial staging and during routine follow-up of stage I/II+III patients
Initial staging Follow-up I/II Follow-up III
(n=561) (n=554) (n=93)
Cost of routine % of Cost of routine % of Cost of routine % of
method total method total method total
Methods
a (due to fp results) costs (due to fp results) costs (due to fp results) costs
H&P 22096 32.4 303353 51.8 46840 53.3
(3347) (23997) (5840)
CXR 11761 17.2 68514 11.7 8135 9.2
(1887) (6477) (239)
SAB 16618 24.4 75736 12.9 10764 12.2
(6421) (23514) (3957)
LNS 17714 26.0 137626 23.6 22209 25.9
(4447) (22672) (4985)
Total: 68189 100 585229







aSee legend Table 2.
bIn a minority of patients other staging methods, e.g. EEG, also were performed on a routine basis during FU I/II (not considered in this table).
Table 4 Distribution of costs (e) for follow-up of localised melanoma by
Breslow thickness and costs per detected ﬁrst recurrence (FR)
Breslow Total No No. Costs per
thickness costs
a patients FR detected FR
pT1 179494 165 5 35900
(40.75 mm)
pT2 214842 154 15 14323
(0.76–1.5 mm)
pT3 153265 136 46 3331
(1.51–4.0 mm)
pT4 44192 41 19 2326
(44.0 mm)
no Breslow 57038 58 10 5704
data
Total: 648832 554 95
aConsiders also other staging methods, e.g. EEG or szintigraphy of the bones
performed on a routine basis in a minority of follow-up patients.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(2), 151–157the metastatic pattern in our 73 stage III patients diagnosed at the
time of second relapse: Although 42% of all patients with a relapse
had distant organs involved, just 19% of the patients had a distant
relapse only, and in 81% of all second relapses at least on loco-
regional site was again involved which was easily be detected by
physical examination at the scheduled visit.
Cost efﬁciency/patients survival
Previous papers have estimated the costs of treating cutaneous
melanoma, with more (Basse `res et al, 1995; Mooney et al, 1997)
or less (Fader et al, 1998; Tsao et al, 1998) emphasis on the costs
of melanoma follow-up. To evaluate a particular screening method
from a health economic point of view, our study focused on the
relationship of efﬁcacy to detect metastases during initial staging
and follow-up in stage I/II and stage III in comparison to the over-
all costs and the cost per metastasis detected for each screening
method. Although ﬁnancial resources allocated to physical exami-
nations proofed to be the absolutely highest (Table 3), the costs
per detected metastasis were in all phases the lowest. This ﬁnding
is in agreement with a report by French authors (Basse `res et al,
1995).
Sonography of the lymph nodes was the most efﬁcient technical
method to detect relapses (range: 10–16%) in all phases of follow-
up. This is in line with recent reports suggesting that lymph nodes
sonography improves early detection of locoregional metastases
(Tregnaghi et al, 1997; Blum et al, 2000). The efﬁciency-costs ratio
in our study was best at initial staging and the follow-up in stage
III.
In conclusion, the results of this retrospective study cast serious
doubt on the efﬁciency of expensive routine imaging procedures at
initial staging and during early phases of melanoma disease. Tech-
nical screening methods detected 20 occult recurrences out of 95
ﬁrst relapses in the entire stage I/II cohort, but comprised roughly
50% of follow-up costs in this monocentric German setting. Since
survival seems not to be affected by follow-up activities at present,
there is little justiﬁcation for such an investment. Prospective
evaluation of intensive follow-up programs in breast carcinoma
has similarly shown a lack of effect on health related quality of life
and survival (GIVIO-Investigators, 1994; Rosselli Del Turco et al,
1994), and data on effectiveness of follow-up in colo-rectal cancer
gave inconsistent results (Kjeldsen et al, 1997; Rosen et al, 1998;
Northover, 2000), thus indicating that prospective studies would
shed more light on the real value of various follow-up procedures
for melanoma patients.
Follow-up of melanoma patients with ‘low-risk’ melanomas
(50.75 mm) is highly ineffective and therefore cost-intensive
(Table 4). With increasing tumour thickness costs per detected
metastasis dropped. There is no question about the importance
of physical examinations for patients’ education, reassurance,
detection of surgically treatable relapses and other primary melano-
mas. Based on the results of this retrospective study a
recommended schedule for initial screening and follow-up is given
in Table 5.
ACKNOWLEDGEMENTS
Many thanks to Mrs M Vazansky for her helpful support in
preparing this manuscript.
REFERENCES
Ardizzoni A, Grimaldi A, Repetto L, Bruzzone M, Sertoli MR, Rosso R (1987)
Stage I-II melanoma: the value of metastatic work-up. Oncology 44: 87–89
Basse `res N, Grob JJ, Richard MA, Thirion X, Zarour H, Noe C, Collet-Vilette
AM, Lota I, Bonerandi JJ (1995) Cost-effectiveness surveillance of stage I
melanoma. Dermatology 191: 199–203
Bastien M, Tessier MH, Legoux B, Litoux P, Bureau B, Dre ￿no B (1997)
Usefulness of paraclinical follow-up in stage I melanoma. Arch Dermatol
133: 1462–1463
Baughan CA, Hall VL, Leppard BJ, Perkins PJ (1993) Follow-up in stage I
cutaneous malignant melanoma: an audit. Clin Oncol (R Coll Radiol) 5:
174–180
Blum A, Schlagenhauff B, Stroebel W, Breuninger H, Rassner G, Garbe C
(2000) Ultrasound examination of regional lymph nodes signiﬁcantly
improves early detection of locoregional metastases during follow-up of
patients with cutaneous melanoma. Cancer 88: 2534–2539
Conference NC (1992) Diagnosis and treatment of early melanoma. JAMA
268: 1314–1319
Dicker TJ, Kavanagh GM, Herd RM, Ahmad T, McLaren KM, Chetty U,
Hunter JAA (1999) A rational approach to melanoma follow-up in
patients with primary cutaneous melanoma. Br J Dermatol 140: 249–254
Eggermont AM (1996) Nachbeobachtung von Patienten mit einem Melanom
im Stadium I nach Exzision des Prima ¨rtumors: einfach und kostenefﬁzient.
Onkologe 2: 476–480
Fader DJ, Wise CG, Normolle DP, Johnson TM (1998) The multidisciplinary
melanoma clinic: a cost outcomes analysis of specialty care. J Am Acad
Dermatol 38: 742–751
Fusi S, Ariyan S, Sternlicht A (1993) Data on ﬁrst recurrence after treatment
for malignant melanoma in a large patient population. Plast Reconstr Surg
91: 94–98
GIVIO-Investigators (1994) Impact of follow-up testing on survival and
health-related quality of life in breast cancer patients: a multicenter rando-
mized controlled trial. JAMA 271: 1587–1592
Goerz G, Schulte-Beerbuhl R, Roder K, Schoppe WD, Munchhoff C, Jungblut
RM (1986) Malignant melanoma: which examinations are useful in staging
and follow up?. Dtsch Med Wochenschr 111: 1230–1233
Hormbrey E, Banwell P, Gillespie P, Budny P (2000) Melanoma follow-up:
protocols and practice. Br J Dermatol 142:585
Huang CL, Provost N, Marghoob AA, Kopf AW, Levin L, Bart RS (1998)
Laboratory tests and imaging studies in patients with cutaneous malignant
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